source
- GSK to acquire Nuvalent for $11 billion, adding two lung-cancer drugs under FDA reviewGSK announced a deal to buy Massachusetts‑based biotech Nuvalent for $11 billion. The acquisition brings two experimental lung‑cancer medicines that are currently under review by the U.S. Food and…
- Stealthy biotech Treeline Biosciences to go public via reverse merger with Standard BioToolsTreeline Biosciences announced a plan to become a public company through a reverse merger with microfluidics firm Standard BioTools. The transaction will give Standard shareholders about 15.5% of…